504 related articles for article (PubMed ID: 24772955)
1. Alkaptonuria: a very rare metabolic disorder.
Aquaron R
Indian J Biochem Biophys; 2013 Oct; 50(5):339-44. PubMed ID: 24772955
[TBL] [Abstract][Full Text] [Related]
2. Urine homogentisic acid and tyrosine: simultaneous analysis by liquid chromatography tandem mass spectrometry.
Hughes AT; Milan AM; Christensen P; Ross G; Davison AS; Gallagher JA; Dutton JJ; Ranganath LR
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jul; 963():106-12. PubMed ID: 24952314
[TBL] [Abstract][Full Text] [Related]
3. Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone.
Preston AJ; Keenan CM; Sutherland H; Wilson PJ; Wlodarski B; Taylor AM; Williams DP; Ranganath LR; Gallagher JA; Jarvis JC
Ann Rheum Dis; 2014 Jan; 73(1):284-9. PubMed ID: 23511227
[TBL] [Abstract][Full Text] [Related]
4. Oxidative stress and mechanisms of ochronosis in alkaptonuria.
Braconi D; Millucci L; Bernardini G; Santucci A
Free Radic Biol Med; 2015 Nov; 88(Pt A):70-80. PubMed ID: 25733348
[TBL] [Abstract][Full Text] [Related]
5. Conditional targeting in mice reveals that hepatic homogentisate 1,2-dioxygenase activity is essential in reducing circulating homogentisic acid and for effective therapy in the genetic disease alkaptonuria.
Hughes JH; Liu K; Plagge A; Wilson PJM; Sutherland H; Norman BP; Hughes AT; Keenan CM; Milan AM; Sakai T; Ranganath LR; Gallagher JA; Bou-Gharios G
Hum Mol Genet; 2019 Dec; 28(23):3928-3939. PubMed ID: 31600782
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of antioxidant drugs for the treatment of ochronotic alkaptonuria in an in vitro human cell model.
Tinti L; Spreafico A; Braconi D; Millucci L; Bernardini G; Chellini F; Cavallo G; Selvi E; Galeazzi M; Marcolongo R; Gallagher JA; Santucci A
J Cell Physiol; 2010 Oct; 225(1):84-91. PubMed ID: 20648626
[TBL] [Abstract][Full Text] [Related]
7. Development of an in vitro model to investigate joint ochronosis in alkaptonuria.
Tinti L; Taylor AM; Santucci A; Wlodarski B; Wilson PJ; Jarvis JC; Fraser WD; Davidson JS; Ranganath LR; Gallagher JA
Rheumatology (Oxford); 2011 Feb; 50(2):271-7. PubMed ID: 20952450
[TBL] [Abstract][Full Text] [Related]
8. Homogentisic acid induces morphological and mechanical aberration of ochronotic cartilage in alkaptonuria.
Bernardini G; Leone G; Millucci L; Consumi M; Braconi D; Spiga O; Galderisi S; Marzocchi B; Viti C; Giorgetti G; Lupetti P; Magnani A; Santucci A
J Cell Physiol; 2019 May; 234(5):6696-6708. PubMed ID: 30341892
[TBL] [Abstract][Full Text] [Related]
9. Nutritional interventions for patients with alkaptonuria: A minireview.
Imrich R; Zatkova A; Lukacova O; Sedlakova J; Zanova E; Vlcek M; Penesova A; Radikova Z; Havranova A; Ranganath L
Endocr Regul; 2023 Jan; 57(1):61-67. PubMed ID: 36966367
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in management of alkaptonuria (invited review; best practice article).
Ranganath LR; Jarvis JC; Gallagher JA
J Clin Pathol; 2013 May; 66(5):367-73. PubMed ID: 23486607
[TBL] [Abstract][Full Text] [Related]
11. An update on molecular genetics of Alkaptonuria (AKU).
Zatkova A
J Inherit Metab Dis; 2011 Dec; 34(6):1127-36. PubMed ID: 21720873
[TBL] [Abstract][Full Text] [Related]
12. Calculi and intracellular ochronosis in the submandibular tissues from a patient with alkaptonuria.
Taylor AM; Wilson PJ; Ingrams DR; Helliwell TR; Gallagher JA; Ranganath LR
J Clin Pathol; 2010 Feb; 63(2):186-8. PubMed ID: 20154043
[TBL] [Abstract][Full Text] [Related]
13. A novel ex vivo organotypic culture model of alkaptonuria-ochronosis.
Tinti L; Spreafico A; Chellini F; Galeazzi M; Santucci A
Clin Exp Rheumatol; 2011; 29(4):693-6. PubMed ID: 21813063
[TBL] [Abstract][Full Text] [Related]
14. Alkaptonuria presenting with ochronotic spondyloarthropathy.
Al-Mahfoudh R; Clark S; Buxton N
Br J Neurosurg; 2008 Dec; 22(6):805-7. PubMed ID: 19085367
[TBL] [Abstract][Full Text] [Related]
15. Homogentisic acid induces autophagy alterations leading to chondroptosis in human chondrocytes: Implications in Alkaptonuria.
Galderisi S; Milella MS; Rossi M; Cicaloni V; Rossi R; Giustarini D; Spiga O; Tinti L; Salvini L; Tinti C; Braconi D; Millucci L; Lupetti P; Prischi F; Bernardini G; Santucci A
Arch Biochem Biophys; 2022 Mar; 717():109137. PubMed ID: 35090868
[TBL] [Abstract][Full Text] [Related]
16. Ochronotic pigmentation is caused by homogentisic acid and is the key event in alkaptonuria leading to the destructive consequences of the disease-A review.
Ranganath LR; Norman BP; Gallagher JA
J Inherit Metab Dis; 2019 Sep; 42(5):776-792. PubMed ID: 31282009
[TBL] [Abstract][Full Text] [Related]
17. Ashy ears.
Rallis E; Kintzoglou S
ScientificWorldJournal; 2010 Aug; 10():1530-1. PubMed ID: 20694448
[TBL] [Abstract][Full Text] [Related]
18. A molecular spectroscopy approach for the investigation of early phase ochronotic pigment development in Alkaptonuria.
Bernini A; Petricci E; Atrei A; Baratto MC; Manetti F; Santucci A
Sci Rep; 2021 Nov; 11(1):22562. PubMed ID: 34799606
[TBL] [Abstract][Full Text] [Related]
19. Use of nitisinone in patients with alkaptonuria.
Suwannarat P; O'Brien K; Perry MB; Sebring N; Bernardini I; Kaiser-Kupfer MI; Rubin BI; Tsilou E; Gerber LH; Gahl WA
Metabolism; 2005 Jun; 54(6):719-28. PubMed ID: 15931605
[TBL] [Abstract][Full Text] [Related]
20. A Mimic of Ankylosing Spondylitis, Ochronosis: Case Report and Review of the Literature.
Chu P; Cuellar MC; Bracken SJ; Tarrant TK
Curr Allergy Asthma Rep; 2021 Mar; 21(3):19. PubMed ID: 33666743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
